Nothing Special   »   [go: up one dir, main page]

Swanton et al., 2014 - Google Patents

Early prognosis of multiple sclerosis

Swanton et al., 2014

Document ID
1808084010968681285
Author
Swanton J
Fernando K
Miller D
Publication year
Publication venue
Handbook of clinical neurology

External Links

Snippet

Establishing the prognosis for multiple sclerosis (MS) early in the disease course is critically important for patients who develop this disease. Potentially, this information could be used to guide the selection of which disease modifying therapy (if any) should be started in which …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes

Similar Documents

Publication Publication Date Title
Swanton et al. Early prognosis of multiple sclerosis
Soldan et al. Cognitive reserve and long-term change in cognition in aging and preclinical Alzheimer's disease
Ferracci et al. Hashimoto's encephalopathy: epidemiologic data and pathogenetic considerations
Brownlee et al. Clinically isolated syndromes and the relationship to multiple sclerosis
Córdoba New assessment of hepatic encephalopathy
Reiss et al. Sex differences in cerebral volumes of 8-year-olds born preterm
Hughes et al. Brain cholesterol metabolism, oxysterols, and dementia
Martin et al. Evidence that volume of anterior medial temporal lobe is reduced in seniors destined for mild cognitive impairment
Weinberger Computed tomography (CT) findings in schizophrenia: speculation on the meaning of it all
Siritho et al. The prognostic significance of cerebrospinal fluid in multiple sclerosis
Hansen et al. Seizure control and cognitive improvement via immunotherapy in late onset epilepsy patients with paraneoplastic versus GAD65 autoantibody-associated limbic encephalitis
Shang et al. Visual memory as a potential cognitive endophenotype of attention deficit hyperactivity disorder
Schermuly et al. Neuropsychiatric symptoms and brain structural alterations in Fabry disease
Kuroda et al. Novel clinical grading of delayed neurologic sequelae after carbon monoxide poisoning and factors associated with outcome
Lee et al. Effects of lacunar infarctions on cognitive impairment in patients with cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy
Weinstock-Guttman et al. The rs2030324 SNP of brain-derived neurotrophic factor (BDNF) is associated with visual cognitive processing in multiple sclerosis
Switzer et al. Longitudinal decrease in blood oxygenation level dependent response in cerebral amyloid angiopathy
Panou et al. Early signs of memory impairment among multiple sclerosis patients with clinically isolated syndrome
Mole et al. Genetic risk of dementia modifies obesity effects on white matter myelin in cognitively healthy adults
Zhu et al. Serum hepatocyte growth factor is associated with small vessel disease in Alzheimer’s dementia
Sandi et al. Prevalence of cognitive impairment among Hungarian patients with relapsing-remitting multiple sclerosis and clinically isolated syndrome
Chan Early diagnosis, monitoring, and treatment of optic neuritis
Ehling et al. Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: a prospective observational clinical trial
Hinotsu et al. The validity of atypical psychosis diagnostic criteria to detect anti-NMDA receptor encephalitis with psychiatric symptoms
Ghezzi et al. Neurofilament Light Chain in Adult and Pediatric Multiple Sclerosis: A Promising Biomarker to Better Characterize Disease Activity and Personalize MS Treatment